|  |
| --- |
| The PBAC agenda primarily consists of applications relating to the new listing of a drug or vaccine on the PBS or the National Immunisation Program.The PBAC agenda consists of the following:**1 Minutes of Previous Meeting****2 Chairman’s report (verbal)****3 Matters arising from the minutes****4 Matters arising/outstanding****5 New drug applications****6 Requests for changes to listings****7 Resubmissions****8 Pricing Matters****9 Matters relating to PBS review****10 Subcommittee and Working Party reports****11 Other business****12 Correspondence****13 Further information****14 Late papers****15 Tabled papers**Consumers will have the opportunity to provide comments on new drug submissions (item 5), changes to listings (item 6) and resubmissions (item 7). In many circumstances, consumers will be able to comment on items in other sections of the agenda. The submissions for which input is sought will be listed in alphabetical order by drug name. There is no provision for consumer comments to the PBAC on agenda item 8 which relates to pricing matters. Pharmaceutical benefits listed in the Schedule fall into three broad categories:*Unrestricted benefits* – have no restrictions on their therapeutic uses; *Restricted benefits* – can only be prescribed for specific therapeutic uses (noted as Restricted benefit); and *Authority required benefits* – Authority required benefits fall into two categories: * *Authority required benefits* require prior approval from Medicare Australia or the DVA (noted as Authority required)
* *Authority required (STREAMLINED) benefits* do not require prior approval from Medicare Australia or the DVA but require the recording of a streamlined authority code (noted as Authority required (STREAMLINED)).

Submissions are categorised broadly as major or minor:* *Major:* Submissions to list new medicines on the Schedule of Pharmaceutical Benefits or to make substantial changes to current listings are generally classified as major submissions. Major submissions require presentation of an economic evaluation.
* *Minor:* Submissions that relate to new forms of previously listed products and changes to the conditions of use e.g. change in maximum quantity/repeats or clarifying the wording of a restriction (while not altering the intended use) are considered to be minor submissions. Minor submissions do not usually require the presentation of an economic evaluation.
 |

| **Submission type**(new listing, change to listing) | **Drug Name, form(s), strength(s) and Sponsor**(Drug name, form, strength, Trade name®, Sponsor) | **Drug Type and Use**(What is the drug used to treat?) | **Listing requested by Sponsor / Purpose of Submission**(Includes type of listing requested (unrestricted, restricted benefit, authority required) and restriction wording. If restriction is lengthy it may be paraphrased.) |
| --- | --- | --- | --- |
| New listing(Minor Submission) | ADALIMUMABInjection 40 mg pre-filled penInjection 40 mg pre-filled syringeInjection 40 mg vialIdacio®Fresenius Kabi Australia Pty Limited | Severe Crohn disease; moderate to severe ulcerative colitis; severe active juvenile idiopathic arthritis; complex refractory fistulising Crohn disease; severe active rheumatoid arthritis; severe psoriatic arthritis; ankylosing spondylitis; severe chronic plaque psoriasis; moderate to severe hidradenitis suppurativa | To request an Authority Required (STREAMLINED) listing of a new biosimilar adalimumab under the same conditions as the reference biologic.  |
| Change to listing (Minor Submission) | ADALIMUMABInjection 40 mg pre-filled syringeInjection 40 mg auto-injectorHadlima®Merck Sharp & Dohme (Australia) Pty Ltd | Severe Crohn disease; complex refractory fistulising Crohn disease; moderate to severe ulcerative colitis; severe active juvenile idiopathic arthritis; adult patients with a history of juvenile idiopathic arthritis; severe psoriatic arthritis; ankylosing spondylitis; severe chronic plaque psoriasis; severe active rheumatoid arthritis | To request an Authority Required (STREAMLINED) listing for the biosimilar in the continuing treatment phase; to request an Authority Required (telephone) for the biosimilar in the initial treatment phase; and to request that use of the biosimilar not count as treatment failure.  |
| New listing (Minor Submission) | ADRENALINEI.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injectorI.M. injection 300 micrograms in 0.3 mL single dose syringe auto-injectorI.M. injection 500 micrograms in 0.3 mL single dose syringe auto-injectorAnapen®Allergy Concepts Pty Ltd | Acute allergic reaction with anaphylaxis | To request the Authority Required listing of an alternative brand of adrenaline auto-injector under the same conditions as other brands of adrenaline currently listed on the PBS and to request the Authority Required listing of a new strength of adrenaline auto-injector.  |
| New listing (Minor Submission) | AMINO ACID FORMULA WITH VITAMINS AND MINERALS WITHOUT LYSINE AND LOW IN TRYPTOPHANSachets containing oral powder 24 gSachets containing oral powder 25 gGA Gel®GA Express 15®Vitaflo Australia Pty Limited | Pyridoxine dependent epilepsy | To request a Restricted Benefit listing for the management of pyridoxine dependent epilepsy.  |
| New listing(Major Submission) | APALUTAMIDETablet 60 mgErlyand®Janssen-Cilag Pty Ltd | Prostate cancer | Resubmission to request an Authority Required (Telephone) listing for the treatment of castration resistant prostate cancer with no distant metastasis on conventional imaging. |
| Change to listing (Minor Submission) | APOMORPHINESolution for subcutaneous infusion containing apomorphine hydrochloride hemihydrate 50 mg in 10 mL pre-filled syringeMovapo PFS®Stada Pharmaceuticals Australia Pty Limited | Parkinson’s disease | To request General Schedule, Authority Required (STREAMLINED) listing for the continuing treatment of Parkinson’s disease following initiation with the current Section 100 (Highly Specialised Drugs Program) listings.  |
| New listing(Major Submission) | BECLOMETASONE DIPROPIONATE + FORMOTEROL FUMARATE DIHYDRATE + GYLCOPYRRONIUMPressurised inhalation containing beclometasone dipropionate 100 micrograms with formoterol fumarate dihydrate 6 micrograms and glycopyrronium 10 micrograms (as bromide) per dose, 120 dosesTrimbow®Chiesi Australia Pty Ltd | Chronic obstructive pulmonary disease (COPD) | To request an Authority Required (STREAMLINED) listing for maintenance treatment of moderate to severe COPD. |
| New listing (Minor Submission) | BEVACIZUMABSolution for I.V. infusion 100 mg in 4 mLSolution for I.V. infusion 400 mg in 16 mLMVASI®Amgen Australia Pty Limited | Metastatic colorectal cancer (mCRC); advanced stage IIIB, IIIC or stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer; advanced carcinoma of the cervix; stage IV (metastatic) non-small cell lung cancer (NSCLC); relapsed or recurrent glioblastoma | To request Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing of a new biosimilar bevacizumab under the same conditions as the reference biologic. |
| Change to listing(Major Submission) | CABOZANTINIBTablet 20 mgTablet 40 mgTablet 60 mgCabometyx®Ipsen Pty Ltd | Renal cell carcinoma (RCC) | Resubmission to request an extension to the current Authority Required (STREAMLINED) listing for the treatment of Stage IV clear cell variant RCC to include patients who have not been previously treated with a tyrosine kinase inhibitor (TKI). |
| New listing(Major Submission) | CARIPRAZINECapsule 1.5 mgCapsule 3 mgCapsule 4.5 mgCapsule 6 mgReagila®Seqirus (Australia) Pty Ltd | Schizophrenia | To request an Authority Required (STREAMLINED) listing for the treatment of schizophrenia. |
| New listing(Major Submission) | CEMIPLIMABSolution for IV infusion 350 mg in 7 mLLibtayo®Sanofi-Aventis Australia Pty Ltd | Squamous cell carcinoma (SCC) | To request Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing for the treatment of metastatic or locally advanced cutaneous SCC in patients who are not candidates for curative surgery or curative radiation. |
| New listing(Major Submission) | CRISABOROLEOintment 2%, 30 gOintment 2%, 60 gStaquis®Pfizer Australia Pty Ltd | Atopic dermatitis | Resubmission to request an Authority Required (STREAMLINED) listing for the treatment of mild to moderate atopic dermatitis. |
| Change to listing(Major Submission) | DAPAGLIFLOZINTablet 10 mgForxiga®AstraZeneca Pty Ltd | Heart failure | To request an extension of the current Authority Required (STREAMLINED) listing to include the treatment of heart failure in patients with reduced ejection fraction. |
| New listing (Minor Submission) | DEFERASIROXDispersible tablet 125 mgDispersible tablet 250 mg Dispersible tablet 500 mgDeferasirox Juno®Juno Pharmaceuticals Pty Ltd | Chronic iron overload | To request a Section 100 (Highly Specialised Drugs Program) Authority Required listing for a new form of deferasirox for the treatment of chronic iron overload. |
| Change to listing(Major Submission) | DUPILUMABInjection 200 mg in 1.14 mL single dose pre-filled syringeInjection 300 mg in 2 mL single dose pre-filled syringeDupixent®Sanofi-Aventis Australia Pty Ltd | Asthma | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of severe uncontrolled asthma. |
| New listing(Other) | DUPILUMABInjection 200 mg in 1.14 mL single use pre-filled syringe Injection 300 mg in 2 mL single use pre-filled syringeDupixent®Sanofi-Aventis Australia Pty Ltd | Atopic dermatitis  | To request that the PBAC review a revised proposal following the March 2020 recommendation for dupliumab for the treatment of patients with chronic severe atopic dermatitis who have had an inadequate response to topical therapies.  |
| Change to listing (Major Submission) | DURVALUMABSolution concentrate for I.V. infusion 120 mg in 2.4 mLSolution concentrate for I.V. infusion 500 mg in 10 mLImfinzi®AstraZeneca Pty Ltd | Small cell lung cancer (SCLC) | To request a Section 100 (Efficient Funding of Chemotherapy Program) Authority Required (STREAMLINED) listing in combination with etoposide and platinum-basedchemotherapy for the first-line treatment of extensive-stage SCLC. |
| Change to listing (Major Submission) | ECULIZUMABSolution concentrate for I.V. infusion 300 mg in 30 mLSoliris®Alexion Pharmaceuticals Australasia Pty Ltd | Neuromyelitis optica spectrum disorder (NMOSD) | To request an Authority Required (Written) listing for the treatment of patients with relapsing NMOSD who are anti-aquaporin-4 (AQP4) antibody positive. |
| New listing(Major Submission) | ELOTUZUMABPowder for IV infusion 300 mgPowder for IV infusion 400 mgEmpliciti®Bristol-Myers Squibb Australia Pty Ltd | Multiple myeloma | To request Section 100 (Efficient Funding of Chemotherapy) Authority Required (Telephone) listing in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma. |
| Change to listing(Minor Submission) | EVOLOCUMABInjection 140 mg in 1 mL single use pre-filled penInjection 420 mg in 3.5 mL single use pre-filled cartridgeRepatha®Amgen Australia Pty Limited | Familial heterozygous hypercholesterolaemia; Non-familial hypercholesterolaemia; Familial homozygous hypercholesterolaemia | To request an amendment to the Authority Required listing to allow general practitioners to initiate treatment in consultation with a specialist. |
| New listing(Major Submission)WITHDRAWN | FILGOTINIBTablet 100 mgTablet 200 mgJyseleca®Gilead Sciences Pty Ltd | Rheumatoid arthritis | To request an Authority Required (Written) listing for the treatment of severe active rheumatoid arthritis. |
| New listing(Minor Submission) | FLUOCINOLONE ACETONIDEIntravitreal injection 190 micrograms Iluvien®Specialised Therapeutics Alim Pty Ltd | Diabetic macular oedema | Resubmission to request an amendment to the PBAC’s previously recommended equi-effective doses for fluocinolone acetonide and dexamethasone. |
| New listing(Major Submission) | GALCANEZUMABInjection 120 mg in 1 mL pre-filled penEmgality®Eli Lilly Australia Pty Ltd | Episodic migraine | To request an Authority Required (STREAMLINED) listing for the treatment of adult patients with treatment-resistant episodic migraine. |
| New listing (Minor Submission) | GALCANEZUMABInjection 120 mg in 1 mL pre-filled penEmgality®Eli Lilly Australia Pty Ltd | Chronic migraine | Resubmission to request an Authority Required (STREAMLINED) listing for the prophylactic treatment of patients with chronic migraine who have experienced inadequate response, intolerance or a contraindication to at least three prior preventive migraine medications. |
| Change to listing (Minor Submission) | GLECAPREVIR + PIBRENTASVIRTablet containing 100 mg glecaprevir with 40 mg pibrentasvirMaviret®AbbVie Pty Ltd | Chronic hepatitis C infection | To request an amendment to the Section 100 (Highly Specialised Drugs Program) and General Schedule Authority Required listings to reduce the duration of treatment from 12 weeks to 8 weeks for treatment naïve patients with chronic hepatitis C with compensated cirrhosis.  |
| Change to listing(Major Submission) | GUSELKUMABInjection 100 mg in 1 mL single use pre-filled syringeInjection 100 mg in 1 mL single use pre-filled penTremfya®Janssen-Cilag Pty Ltd | Psoriatic arthritis | To request an Authority Required (Written) listing for the treatment of adult patients with severe psoriatic arthritis who have had an inadequate response to methotrexate and sulfasalazine or leflunomide. |
| New listing (Minor Submission) | HIGH FAT FORMULA WITH VITAMINS, MINERALS AND TRACE ELEMENTS AND LOW IN PROTEIN AND CARBOHYDRATEOral liquid 250 mL, 30KetoVie 4:1®KetoVie 3:1® KetoVie Peptide 4:1®Cortex Health Pty Ltd | Ketogenic diet | To request a Restricted Benefit listing for KetoVie 4:1 and 3:1 and an Authority Required (STREAMLINED) listing for KetoVie Peptide 4:1 as part of a ketogenic diet. |
| New listing (Minor Submission)  | IBRUTINIBTablet 140 mg Tablet 280 mgTablet 420 mg Tablet 560 mgImbruvica®Janssen-Cilag Pty Ltd | Chronic lymphocytic leukaemia (CLL); small lymphocytic lymphoma (SLL); mantle cell lymphoma | To request an Authority Required listing of ibrutinib tablet under the same conditions as the already listed capsule.  |
| New listing(Major Submission) | INFLIXIMABInjection 120 mg in 1 mL pre-filled syringeInjection 120 mg in 1 mL pre-filled penRemsima® SCCelltrion Healthcare Australia Pty Ltd | Rheumatoid arthritisAnkylosing spondylitisPsoriatic arthritis Chronic plaque psoriasis Crohn’s disease Complex refractory fistulising Crohn’s diseaseUlcerative colitis | To request Section 100 (Highly Specialised Drugs Program) and Authority Required listings under the same conditions as infliximab powder for I.V. infusion 100 mg. |
| New listing(Major Submission) | IXAZOMIBCapsule 2.3 mgCapsule 3 mgCapsule 4 mgNinlaro®Takeda Pharmaceuticals Australia Pty Ltd | Multiple myeloma | To request Section 100 (Highly Specialised Drugs Program) Authority Required (Telephone) listing in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma. |
| New listing(Major Submission) | LAROTRECTINIBCapsule 25 mgCapsule 100 mgOral solution 20 mg per mL, 100 mLVitrakvi®Bayer Australia Ltd | Solid tumours harbouring neurotrophic receptor tyrosine kinase (NTRK) gene fusions | To request a Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing for the treatment of locally advanced or metastatic solid tumours harbouring NTRK gene fusions. |
| New listing(Major Submission) | MENINGOCOCCAL POLYSACCHARIDE SEROGROUPS A, C, W-135 AND Y CONJUGATE VACCINEInjection 0.5 mLMenQuadfi®Sanofi-Aventis Australia Pty Ltd | Prevention of meningococcal disease | To request National Immunisation Program (NIP) listing for the prevention of meningococcal disease in toddler and adolescent populations. |
| New listing (Minor Submission) | MESALAZINE Tablet 1600 mgAsacol®Chiesi Australia Pty Ltd | Ulcerative colitis | To request a Restricted Benefit listing of mesalazine for the treatment of mild to moderate ulcerative colitis and maintenance of remission in adults.  |
| New listing (Minor Submission) | MOGAMULIZUMABSolution concentrate for I.V. infusion 20 mg in 5 mLPoteligeo®Kyowa Kirin Australia Pty Ltd | Cutaneous T-Cell Lymphoma (CTCL) | Resubmission to request a Section 100 (Efficient Funding of Chemotherapy) Authority Required (Written) listing for patients with relapsed or refractory CTCL who have previously been treated with at least one prior systemic therapy. |
| Change to listing(Major Submission) | NIVOLUMABIPILIMUMABNivolumab:Injection concentrate for I.V. infusion 40 mg in 4 mL Injection concentrate for I.V. infusion 100 mg in 10 mLOpdivo®Ipilimumab: Injection concentrate for I.V. infusion 50 mg in 10 mL Yervoy®Bristol-Myers Squibb Australia Pty Ltd | Non-small cell lung cancer (NSCLC) | To request Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing in combination with two cycles of chemotherapy for the first-line treatment of patients with Stage IV (metastatic) NSCLC. |
| Change to listing(Major Submission) | NUSINERSENSolution for injection 12 mg in 5 mLSpinraza®Biogen Australia Pty Ltd | Spinal muscular atrophy (SMA) | Resubmission to request an extension to the current Section 100 (Highly Specialised Drugs Program) Authority Required (Written) listing to include the treatment of adults with SMA. |
| New listing(Major Submission) | OBETICHOLIC ACIDTablet 5 mgTablet 10 mgOcaliva®Chiesi Australia Pty Ltd | Primary biliary cholangitis | Resubmission to request an Authority Required (Written) listing for the treatment of primary biliary cholangitis. |
| New listing(Major Submission) | ONASEMNOGENE ABEPARVOVECSolution for injection, customised based on patient weight Zolgensma®Novartis Pharmaceuticals Australia Pty Ltd | Spinal muscular atrophy (SMA) | Submission to request an Authority Required (Written) listing for the treatment of paediatric patients less than 2 years of age with Type 1 SMA. |
| New listing (Minor Submission) | PANCREATIC EXTRACTCapsule (containing enteric coated minimicrospheres) providing not less than 20,000 BP units of lipase activityCapsule (containing enteric coated minimicrospheres) providing not less than 35,000 BP units of lipase activityCreon®Mylan Health Pty Ltd | Pancreatic exocrine insufficiency  | To request an Unrestricted Benefit listing under the same conditions as the already listed strengths. |
| New listing(Major Submission) | PATIROMERSachet, 8.4 g powder for oral liquidSachet, 16.8 g powder for oral liquidVeltassa®Vifor Pharma Pty Ltd | Hyperkalaemia | Resubmission to request an Authority Required (Telephone) listing for the prevention of hyperkalaemia in patients with stage III or greater chronic kidney disease who have experienced a recent episode of hyperkalaemia requiring pharmacological intervention. |
| Change to listing(Major Submission) | PEMBROLIZUMABSolution concentrate for I.V. infusion 100 mg in 4 mLKeytruda®Merck Sharp & Dohme (Australia) Pty Ltd | Squamous cell carcinoma of the head and neck (SCCHN) | To request Section 100 (Efficient Funding of Chemotherapy) Authority Required (STREAMLINED) listing for the first line treatment of recurrent or metastatic SCCHN. |
| Change to listing(Major Submission) | PROGESTERONECapsule 200 mgUtrogestan®Besins Healthcare Australia Pty Ltd | Prevention of preterm birth | To request an extension of the current Authority Required (STREAMLINED) listing to include the prevention of preterm birth in women at risk. |
| Change to listing(Major Submission) | PROGESTERONEPessary 200 mgOripro®Orion Laboratories Pty Ltd | Prevention of preterm birth | To request an extension of the current Authority Required (STREAMLINED) listing to include the prevention of preterm birth in women at risk. |
| Change to listing (Minor Submission) | RIBOCICLIBTablet 200 mgKisqali®Novartis Pharmaceuticals Australia Pty Ltd | Locally advanced or metastatic breast cancer | Resubmission to request an Authority Required listing for the treatment of postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer in combination with fulvestrant. |
| Change to listing(Major Submission) | SACUBITRIL with VALSARTANTablet containing sacubitril 24.3 mg + valsartan 25.7 mg Tablet containing sacubitril 48.6 mg + valsartan 51.4 mgTablet containing sacubitril 97.2 mg + valsartan 102.8 mgEntresto®Novartis Pharmaceuticals Australia Pty Ltd | Heart failure | To request changes to the current Authority Required (STREAMLINED) listing for patients with chronic heart failure with reduced ejection fraction (HF-rEF) to include a broader population of patients. |
| Change to listing (Minor Submission) | SAPROPTERINPowder for oral solution 500 mg Tablet (soluble) 100 mgKuvan®Biomarin Pharmaceutical Australia Pty Ltd | Maternal phenylketonuria (MPKU) | Resubmission to request an Authority Required listing in combination with a Phe-restricted diet for the treatment of MPKU where a Phe-restricted diet does not adequately reduce blood Phe levels. |
| Change to listing(Major Submission) | SECUKINUMABInjection 150 mg in 1 mL pre-filled penCosentyx®Novartis Pharmaceuticals Australia Pty Ltd | Non-radiographic axial spondyloarthritis (nr-axSpA) | To request an Authority Required (Written) listing for the treatment of nr-axSpA. |
| Change to listing(Major and Minor Submissions) | TOFACITINIBTablet 5 mgTablet 10 mgXeljanz®Pfizer Australia Pty Ltd | Ulcerative colitis and other listed indications | Resubmission to request an Authority Required (Written) listing for the treatment of moderate to severe ulcerative colitis and separate submission to consider interchangeability advice. |
| Change to listing (Minor Submission)  | UPADACITINIBTablet 15 mg Rinvoq®Abbvie Pty Ltd | Severe rheumatoid arthritis | Resubmission to request review of the statistical basis upon which the claim of superior effectiveness versus adalimumab for the treatment of patients with severe active RA was not accepted. |
| New listing(Major Submission) | VEDOLIZUMABInjection 108 mg in 0.68 mL pre-filled syringeInjection 108 mg in 0.68 mL pre-filled penEntyvio®Takeda Pharmaceuticals Australia Pty Ltd | Ulcerative colitisCrohn's disease | To request Authority Required listings under the same conditions as vedolizumab powder for injection 300 mg. |
| Sub-committee report(DUSC Analysis) | ADRENALINEI.M. injection 150 micrograms in 0.3 mL single dose syringe auto-injectorI.M. injection 300 microgram in 0.3 mL single dose syringe auto-injectorEpipen®, Adrenaline Mylan® Alphapharm Pty Ltd | Treatment of allergic reaction with anaphylaxis | To assess the utilisation of PBS listed adrenaline for the treatment of allergic reaction with anaphylaxis. |
| Sub-committee report(DUSC Analysis) | ALECTINIBCapsule 150 mgAlecensa® Roche Products Pty Ltd | Treatment of non-small cell lung cancer (NSCLC) | To compare the predicted and actual utilisation of alectinib for the treatment of NSCLC since PBS listing. |
| Sub-committee report(DUSC Analysis) | DENOSUMAB Injection 120 mg in 1.7 mLXgeva®Amgen Australia Pty Ltd | Treatment of osteoporosis | To assess the utilisation of PBS listed denosumab for the treatment of osteoporosis. |
| Sub-committee report(DUSC Analysis) | ECULIZUMAB Solution concentrate for I.V. infusion 300mg in 30 mLSoliris® Alexion Pharmaceuticals Australasia Pty Ltd | Treatment of atypical haemolytic uraemic syndrome (aHUS) | To assess the utilisation of PBS listed eculizumab for the treatment of aHUS. |
| Sub-committee report(DUSC Analysis) | IBRUTINIB Capsule 140 mgImbruvia® Janssen-Cilag Pty Ltd | Treatment of chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) | To compare the predicted and actual utilisation of ibrutinib for the treatment of CLL and SLL since PBS listing. |
| Sub-committee report (DUSC Analysis) | OCRELIZUMABSolution concentrate for I.V. infusion 300 mg in 10 mLOcrevus® Roche Products Pty Ltd | Treatment of relapsing-remitting multiple sclerosis (RRMS). | To compare the predicted and actual utilisation of ocrelizumab for the treatment of RRMS since PBS listing. |